A monoclonal thyroid-stimulating antibody

被引:103
作者
Ando, T
Latif, R
Pritsker, A
Moran, T
Nagayama, Y
Davies, TF
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Hybridoma Shared Res Facil, New York, NY 10029 USA
[3] CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA
[4] Nagasaki Univ, Sch Med, Dept Pharmacol 1, Nagasaki 852, Japan
关键词
D O I
10.1172/JCI200216991
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The thyrotropin receptor, also known as the thyroid-stimulating hormone receptor (TSHR), is the primary antigen of Graves disease. Stimulating TSHR antibodies are the cause of thyroid overstimulation and were originally called long-acting thyroid stimulators due to their prolonged action. Here we report the successful cloning and characterization of a monoclonal antibody (MS-1) with TSHR-stimulating activity. The thyroid-stimulating activity of MS-1 was evident at IgG concentrations as low as 20 ng/ml. MS-1 also competed for radiolabeled TSH binding to the native TSHR and was able to compete for TSH-induced stimulation. MS-1 recognized a conformational epitope within the TSHR a (or A) subunit but excluding the receptor cleavage region. Using an assay measuring loss of antibody recognition after cleavage we demonstrated that MS-1, in contrast to TSH, was unable to enhance TSHR posttranslational cleavage. Since receptor cleavage is followed by a subunit shedding and receptor degradation, the functional half-life of the receptor may be extended. The isolation and characterization of MS-1 provides a novel explanation for the prolonged thyroid stimulation in this disease which maybe secondary to the lack of receptor cleavage in addition to the prolonged half-life of IgG itself.
引用
收藏
页码:1667 / 1674
页数:8
相关论文
共 31 条
  • [1] Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites
    Chazenbalk, GD
    Tanaka, K
    Nagayama, Y
    Kakinuma, A
    Jaume, JC
    McLachlan, SM
    Rapoport, B
    [J]. ENDOCRINOLOGY, 1997, 138 (07) : 2893 - 2899
  • [2] Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera
    Chazenbalk, GD
    Jaume, JC
    McLachlan, SM
    Rapoport, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) : 18959 - 18965
  • [3] Is receptor cleavage into two subunits necessary for thyrotropin action?
    Chazenbalk, GD
    McLachlan, SM
    Nagayama, Y
    Rapoport, B
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 225 (02) : 479 - 484
  • [4] Costagliola S, 1998, J IMMUNOL, V160, P1458
  • [5] Couet J, 1996, J BIOL CHEM, V271, P4545
  • [6] The TSH receptor reveals itself
    Davies, T
    Marians, R
    Latif, R
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (02) : 161 - 164
  • [7] Development and characterization of monoclonal antibodies specific for the murine thyrotropin receptor
    Davies, TF
    Bobovnikova, Y
    Weiss, M
    Vlase, H
    Moran, T
    Graves, PN
    [J]. THYROID, 1998, 8 (08) : 693 - 701
  • [8] Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain
    de Bernard, S
    Misrahi, M
    Huet, JC
    Beau, I
    Desroches, A
    Loosfelt, H
    Pichon, C
    Pernollet, JC
    Milgrom, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (01) : 101 - 107
  • [9] Thyrotropin receptor autoantibodies in serum are present at much lower levels than thyroid peroxidase autoantibodies: Analysis by flow cytometry
    Jaume, JC
    Kakinuma, A
    Chazenbalk, GD
    Rapoport, B
    McLachlan, SM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 500 - 507
  • [10] Kaithamana S, 1999, J IMMUNOL, V163, P5157